Can you recommend biotech trade publications for following clinical-stage cell and gene therapy programs?

Yes — for clinical-stage cell and gene therapy programs, these biotech and industry trade publications are especially useful:

Top general biotech trade publications

• Endpoints News — Strong for clinical/biopharma deal flow, trial readouts, regulatory milestones, and company updates.
• BioCentury — Deep industry analysis, especially useful for pipeline strategy, financing, and clinical-stage program tracking.
• Fierce Biotech — Good for fast coverage of clinical updates, layoffs, partnerships, and trial announcements.
• STAT News (biopharma section) — Not a trade publication in the strictest sense, but very good for high-impact biotech and clinical news.
• GEN (Genetic Engineering & Biotechnology News) — Broad biotech coverage with frequent cell/gene therapy stories.
• Nature Biotechnology — More scientific than trade-oriented, but excellent for staying current on platform and translational developments.

Cell and gene therapy–focused sources

• Cell & Gene — Probably the most directly relevant publication for your use case; strong focus on clinical, manufacturing, regulatory, and commercial issues in cell and gene therapy.
• The Cell & Gene Therapy Catapult / CGT publications — Useful for industry trend reports and translational/manufacturing insights.
• Pink Sheet / In Vivo / Scrip (part of Citeline) — Very useful for regulatory and clinical development tracking, especially if you care about FDA/EMA activity.

Regulatory and clinical-trial tracking sources

• FDA press releases and advisory committee materials — Primary source for approvals, CRLs, safety updates, and meeting documents.
• ClinicalTrials.gov — Essential for monitoring trial status changes, enrollment, endpoints, amendments, and site activity.
• EMA news and CHMP agendas/opinions — If you follow ex-US programs.
• MHRA, PMDA, and Health Canada updates — Helpful depending on geography.

Deal/financing and company-tracking sources

• Evaluate Vantage — Useful for pipeline, valuation, and competitive intelligence on clinical-stage assets.
• Biopharma Dive — Good for straightforward reporting on clinical updates and commercial strategy.
• S&P Capital IQ / PitchBook / Citeline — Not publications, but very useful databases for tracking company and program progress.

If you want the best combination

If your goal is specifically to track clinical-stage cell and gene therapy programs, I’d start with:

1. Cell & Gene
2. Endpoints News
3. BioCentury
4. Fierce Biotech
5. Pink Sheet / Citeline
6. ClinicalTrials.gov
7. FDA updates

If you want, I can also give you:

• a ranked list by usefulness for cell therapy vs gene therapy
• free vs paid options
• or a watchlist workflow for tracking programs across news, trials, and regulators.